Biodexa Pharmaceuticals Plc (BDRX) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -2.33M | -3.3M | -7.45M | -4.81M | -2.94M | -3.88M | -3.51M | -3.54M | -2.9M | -3.11M | -2.21M | -7.09M |
| Operating CF Margin % | - | - | - | - | -3548.19% | -1302.35% | -1519.05% | -756.2% | -1638.42% | -775.06% | -1264.57% | -4219.05% |
| Operating CF Growth % | 68.8% | 31.27% | -153.11% | -23.86% | 16.07% | -9.66% | -21% | -13.87% | -31.04% | 56.15% | -14.78% | -55.4% |
| Net Income | -2.56M | -3.81M | -2.42M | -3.31M | -3.51M | -3.57M | -4.59M | -3.06M | -2.31M | -3.15M | -4.77M | -17.42M |
| Depreciation & Amortization | 48.7K | 140K | 118K | 136K | 140K | 143K | 161K | 182K | 224K | 179K | 654K | 563K |
| Stock-Based Compensation | 0 | 97K | 133K | 150K | 13K | 15K | 23K | 100K | 52K | 37K | 1K | -473K |
| Deferred Taxes | 0 | 0 | -250K | 0 | 0 | -118K | -254K | 124K | -424K | 822K | -987K | 966K |
| Other Non-Cash Items | -1.56M | -1.78M | -2.6M | -487K | 151K | -367K | 506K | -528K | -1.24M | 689K | 865K | 10.83M |
| Working Capital Changes | 1.75M | 2.05M | -2.44M | -1.3M | 262K | -104K | 396K | -232K | 372K | -859K | 1.04M | -590K |
| Change in Receivables | 642.85K | 2.05M | -4.68M | -1.3M | 262K | 103K | 231K | -224K | 372K | -859K | 986K | -493K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -308.93K | -339K | 156K | -754K | -285K | 20K | -203K | -17K | -131K | -147K | 2.66M | -88K |
| Capital Expenditures | -326.82K | -2K | -9K | 0 | -22K | -4K | -29K | -33K | -131K | -189K | -120K | -89K |
| CapEx % of Revenue | - | - | - | - | 26.51% | 1.34% | 12.55% | 7.05% | 74.01% | 47.13% | 68.57% | 52.98% |
| Acquisitions | 17.89K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -337K | 165K | -754K | -263K | 24K | -174K | 16K | 0 | 42K | 2.78M | 1K |
| Cash from Financing | 7.18M | 6.01M | 3.91M | 4.64M | 3.97M | 6.25M | 125K | -78K | 8.89M | -81K | 2.7M | 385K |
| Debt Issued (Net) | -447.23K | -95K | 245K | -93K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 7.65M | 0 | 8.31M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -22.18K | 6.11M | -4.64M | 4.74M | 3.97M | 6.25M | 125K | -78K | 8.89M | -81K | 2.7M | 385K |
| Net Change in Cash | 4.41M | 4.04M | -5.05M | 5.05M | 372K | 1.2M | -1.79M | 6.42M | 2.93M | -1.67M | 1.61M | -3.3M |
| Free Cash Flow | -2.33M | -3.31M | -8.23M | -4.81M | -2.97M | -3.88M | -3.54M | -3.57M | -3.03M | -3.3M | -2.33M | -7.18M |
| FCF Margin % | - | - | - | - | -3574.7% | -1303.69% | -1531.6% | -763.25% | -1712.43% | -822.19% | -1333.14% | -4272.02% |
| FCF Growth % | 71.74% | 31.23% | -177.32% | -23.73% | 16.14% | -8.76% | -16.73% | -8.34% | -29.92% | 54.06% | -4.76% | -56.67% |
| FCF per Share | -10.30 | -13.08 | -132.81 | -1939.87 | -98900.00 | -555000.00 | -999999.00 | -999999.00 | -999999.00 | -999999.00 | -999999.00 | - |
| FCF Conversion (FCF/Net Income) | 0.91x | 0.87x | 3.08x | 1.45x | 0.84x | 1.09x | 0.76x | 1.16x | 1.26x | 0.99x | 0.46x | 0.41x |
| Interest Paid | 0 | 10K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |